Ligand Pharmaceuticals Incorporated
LGND
$210.99
$3.191.54%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 268.09M | 251.23M | 187.58M | 181.49M | 167.13M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 268.09M | 251.23M | 187.58M | 181.49M | 167.13M |
| Cost of Revenue | 91.44M | 92.95M | 76.25M | 75.04M | 28.96M |
| Gross Profit | 176.64M | 158.29M | 111.33M | 106.45M | 138.18M |
| SG&A Expenses | 92.45M | 93.03M | 89.06M | 86.50M | 78.65M |
| Depreciation & Amortization | 32.71M | 32.87M | 33.03M | 33.03M | 32.96M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 220.89M | 222.39M | 201.88M | 198.11M | 144.11M |
| Operating Income | 47.20M | 28.85M | -14.30M | -16.63M | 23.02M |
| Income Before Tax | 158.96M | 62.98M | -84.50M | -161.11M | 2.52M |
| Income Tax Expenses | 34.51M | 14.40M | -8.63M | -28.49M | 6.55M |
| Earnings from Continuing Operations | 124.45 | 48.58 | -75.86 | -132.62 | -4.03 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 124.45M | 48.58M | -75.86M | -132.62M | -4.03M |
| EBIT | 47.20M | 28.85M | -14.30M | -16.63M | 23.02M |
| EBITDA | 80.97M | 63.03M | 19.73M | 18.16M | 58.26M |
| EPS Basic | 6.30 | 2.39 | -3.99 | -7.12 | -0.05 |
| Normalized Basic EPS | 4.64 | -0.57 | -2.60 | -2.70 | -1.37 |
| EPS Diluted | 5.82 | 2.07 | -4.00 | -7.12 | -0.16 |
| Normalized Diluted EPS | 4.29 | -0.68 | -2.61 | -2.70 | -1.37 |
| Average Basic Shares Outstanding | 77.82M | 77.07M | 75.91M | 74.61M | 73.15M |
| Average Diluted Shares Outstanding | 80.88M | 78.72M | 76.51M | 74.61M | 73.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |